Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade
Piegeler, Tobias M.D.*; Votta-Velis, E. Gina M.D., Ph.D.†; Liu, Guoquan Ph.D.‡; Place, Aaron T. Ph.D.§; Schwartz, David E. M.D.‖; Beck-Schimmer, Beatrice M.D.#; Minshall, Richard D. Ph.D.**; Borgeat, Alain M.D.††
Background: Retrospective analysis of patients undergoing cancer surgery suggests the use of regional anesthesia may reduce cancer recurrence and improve survival. Amide-linked local anesthetics have antiinflammatory properties, although the mechanism of action in this regard is unclear. As inflammatory processes involving Src tyrosine protein kinase and intercellular adhesion molecule-1 are important in tumor growth and metastasis, we hypothesized that amide-linked local anesthetics may inhibit inflammatory Src-signaling involved in migration of adenocarcinoma cells.
Methods: NCI-H838 lung cancer cells were incubated with tumor necrosis factor-α in absence/presence of ropivacaine, lidocaine, or chloroprocaine (1 nM–100 μM). Cell migration and total cell lysate Src-activation and intercellular adhesion molecule-1 phosphorylation were assessed. The role of voltage-gated sodium-channels in the mechanism of local anesthetic effects was also evaluated.
Results: Ropivacaine treatment (100 μM) of H838 cells for 20 min decreased basal Src activity by 62% (P = 0.003), and both ropivacaine and lidocaine coadministered with tumor necrosis factor-α statistically significantly decreased Src-activation and intercellular adhesion molecule-1 phosphorylation, whereas chloroprocaine had no such effect. Migration of these cells at 4 h was inhibited by 26% (P = 0.005) in presence of 1 μM ropivacaine and 21% by 1 μM lidocaine (P = 0.004). These effects of ropivacaine and lidocaine were independent of voltage-gated sodium-channel inhibition.
Conclusions: This study indicates that amide-, but not ester-linked, local anesthetics may provide beneficial antimetastatic effects. The observed inhibition of NCI-H838 cell migration by lidocaine and ropivacaine was associated with the inhibition of tumor necrosis factor-α-induced Src-activation and intercellular adhesion molecule-1 phosphorylation, providing the first evidence of a molecular mechanism that appears to be independent of their known role as sodium-channel blockers.
What We Already Know about This Topic
* Regional anesthesia is associated in some clinical studies with reduced risk of metastasis or late mortality in patients undergoing cancer surgery
* Local anesthetics have antiinflammatory effects that may participate in a reduced risk of metastasis, but their mechanisms are unknown
What This Article Tells Us That Is New
* In cellular studies in vitro with lung cancer cells, amide- but not ester-local anesthetics reduced tumor cell migration and reduced signaling pathways important to tumor growth and metastases
* Regional anesthesia might reduce cancer metastasis by direct effects of absorbed amide local anesthetics on tumor cells
LUNG cancer is the leading cause of death from cancer in males and the second leading cause of death in females1
; effective treatment remains a challenge. Even if patients undergo complete tumor resection, including lymphadenectomy, there is still a high rate of relapse because of undetected micrometastasis.2–4
Regional anesthesia with local anesthetics in combination with general anesthesia is commonly used in patients undergoing tumor resection of the lung.5
It is well known that amide-linked local anesthetics – as opposed to ester-linked compounds – can exert inhibitory effects on inflammatory processes,6 e.g.
, as ropivacaine has been shown to possess antiinflammatory properties in a model of pulmonary inflammation.7
Also, the systemic use of lidocaine in patients undergoing colo-rectal surgery led to a decrease in inflammatory cytokine release as well as a shortened hospital stay.8
There is increasing evidence that inflammatory mechanisms may play an important role in the development and growth of cancer metastasis.9
Cytokines such as tumor necrosis factor-α (TNF-α) increase the expression of intercellular adhesion molecule-1 (ICAM-1), a cell surface receptor required for leukocyte adhesion10
and tumor invasion,11
in the H838 nonsmall cell lung cancer cell line.12
ICAM-1 also facilitates tumor cell extravasation via
the binding of neutrophils.13
TNF-α is known to induce activation of Src protein tyrosine kinase, which functions as a regulator of endothelial permeability.14
Src-mediated phosphorylation of ICAM-1 is necessary for neutrophil adhesion to the endothelium during acute lung inflammation and injury,15
a process considered to induce vascular hyperpermeability.10
In addition, Src is involved in signaling epithelial-to-mesenchymal transformation and extravasation of cancer cells,16
processes that are necessary for solid tumor metastasis.18
Recently published retrospective analysis of patients undergoing cancer surgery showed a possible benefit of the perioperative use of regional anesthesia. Long-term survival after colon cancer surgery19
and cancer recurrence after radical prostatectomy for prostate cancer20
or breast cancer21
were significantly improved by epidural anesthesia/analgesia compared with patient-controlled analgesia with opioids. The mechanism by which regional anesthesia might prove to be beneficial at the molecular level in this context is not yet known. We hypothesized that this effect might be related to the antiinflammatory properties of local anesthetics.
The primary goal of this study was to determine whether amide-linked local anesthetics (ropivacaine and lidocaine) attenuate TNF-α-induced Src activation and ICAM-1 phosphorylation in H838 human lung cancer cells and whether these effects are because of the inhibition of voltage-gated sodium channels (VGSC). Second, we examined whether lidocaine, ropivacaine, or chloroprocaine inhibit migration of this cancer cell line in vitro.
Materials and Methods
The human NCI-H838 lung cancer cell line (CRL-5844, ATCC, Rockville, MD), isolated from an 80-yr-old patient with stage 3B nonsmall cell lung cancer, was cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine (all from Gibco Invitrogen, Carlsbad, CA). Experiments were performed with 70–100% confluent cells from passages 49–55. Before the experiments, cells were grown in reduced-serum (RPMI + 1% FBS) for 16 h. All cells were maintained in 5% CO2 and 95% room air in a water-jacketed 37°C incubator.
Cell monolayers were incubated either with Escherichia coli serotype 055:B5 lipopolysaccharide (Sigma-Aldrich) at a concentration of 4 μg/ml diluted in RPMI + 1% FBS medium for 4 h, or with TNF-α (Gibco Invitrogen) at a concentration of 20 ng/ml, also diluted in RPMI-1% FBS, for 20 min for Western blot analysis or 4 h for assessment of cell migration and cytotoxic effects.
Ropivacaine 0.5% (Naropin®, APP Pharmaceuticals, Schaumburg, IL), lidocaine 2% (APP Pharmaceuticals), or chloroprocaine 3% (Bedford Laboratories, Bedford, OH) were diluted with RPMI + 1% FBS medium to achieve the concentrations tested (1 nM–100 μM) for the treatment of H838 cells in presence or absence of TNF-α or lipopolysaccharide. For some experiments, cells were pretreated with the VGSC agonist veratridine (Sigma-Aldrich) for 30 min or with the VGSC antagonist tetrodotoxin (Sigma-Aldrich) for 10 min.
Cytotoxicity was measured using the Cytotoxicity Detection KitPlus (Roche, Indianapolis, IN), following the instructions by the manufacturer. The assay measures the activity of lactate dehydrogenase as a marker for cytotoxicity in cell culture supernatants. NCI-H838 cells were incubated for 4 h in low serum RPMI-1640 medium (1% FBS, 1% penicillin/streptomycin, 1% L-glutamine) with different concentrations of ropivacaine, lidocaine, or chloroprocaine (1 nM–100 μM) in presence or absence of TNF-α at a concentration of 20 ng/ml. Thirty min before the end of the experiment, some cells were lysed by the addition of 10% Triton-X 100 (Sigma-Aldrich) to measure the maximal release of lactate dehydrogenase. Then the supernatant was collected and centrifuged for 5 min at 700 g to remove all cellular debris. Lactate dehydrogenase content was determined by the measurement of red formazan, derived from the yellow tetrazolium salt INT (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride) by a catalyst after reduction of NAD+ to NADH + H+ by lactate dehydrogenase. Cytotoxicity was then calculated according to the following formula:
Equation (Uncited)Image Tools
Cell Harvest and Lysis
After the end of the experiment, cells were washed once with ice-cold Dulbecco's phosphate-buffered saline (Cellgro, Manassas, VA) and lysed with radioimmunoprecipitation buffer (Boston Bioproducts, Ashland, MA) supplemented with protease inhibitor cocktail, 200 mM phenylmethylsulfonylfluoride, 1 mM EDTA, 1 mM sodium-fluoride, and 1 mM sodium-orthovanadate (all from Sigma-Aldrich). After a brief sonification and 10 min centrifugation at 4°C and 13,200 rpm in an Eppendorf 5415R microcentrifuge (Eppendorf AG, Hamburg, Germany), the supernatant was collected and stored at −20°C until further use. Total protein concentration was determined using a BCA protein assay kit (Pierce Thermo Fisher Scientific, Rockford, IL) according to the manufacturer's instructions, using albumin to generate a standard curve.
Western Blot Analysis
Before boiling the lysates for 5 min, 6× Laemmli sample buffer (Boston Bioproducts) was added at a final concentration of 1× as well as 30 mM Dithiothreitol (DTT, Biorad, Hercules, CA). Equal amounts of protein (10 μg) were loaded in each lane of a 10% polyacrylamide gel for sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE). After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane (Biorad) with 5% blotting grade nonfat dry milk (Biorad) dissolved in Tris-buffered saline with 0.05% TWEEN-20 (TBST) (Sigma-Aldrich) for 30 min. The membranes were then probed with primary antibodies in TBST for 2 h on a shaker at room temperature or at 4°C overnight. Three washes with TBST were followed by incubation of the membrane with horseradish-peroxidase-conjugated secondary antibody (KPL, Gaithersburg, MD) in 5% milk in TBST for 1 h on a shaker at room temperature. After four washes with TBST, enhanced chemiluminescence solution (Thermo Scientific) was used to visualize the bands on HyBlot CL film (Denville, South Plainfield, NJ). To detect the total amount of ICAM-1 or Src on the same membranes after detection of the phosphorylated forms of the proteins, the antibodies were removed from the membranes using Restore Western Blot Stripping Buffer (Thermo Scientific). Subsequently, the membranes were blocked and reprobed with primary and secondary antibodies, as stated above.
Primary antibodies for pY419 Src and (total) Src were purchased from Cell Signaling Technologies (Danvers, MA) and for pY512 ICAM-1 and (total) ICAM-1 from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Migration Assay
NCI-H838 lung cancer cells were suspended at a concentration of 106/ml and were stained with fluorescent dye (Cytoselect®, Cell Biolabs, San Diego, CA). Then, 105 NCI-H838 cells were resuspended in 300 μl RPMI-1640 medium with 0% FBS and no other supplements or with different concentrations of ropivacaine, lidocaine, or chloroprocaine (1 pM–100 μM) and were incubated for 15 min at room temperature and placed into the upper chamber of a 6.5-mm Transwell® polycarbonate membrane insert with 8-μM pores (Corning Life Sciences, Lowell, MA). The inserts were then placed into 500 μl complete medium (RPMI-1640, 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine, plus the same concentration of local anesthetic as present in the upper chamber) in a 24-well plate. To assess the reversibility of the inhibition of cell migration, cells were washed three times after incubation with ropivacaine before resuspending in 300 μl RPMI-1640 medium and placement into the upper chamber of a Transwell® insert. After 4 h, all inserts were removed from the well. The remaining fluid in the upper chamber was removed and the inserts were placed into fresh wells filled with cell detachment and lysis solution. A Wallac Victor2® microplate reader (Perkin Elmer, Waltham, MA) was used to detect fluorescence at 485/535 nM (excitation/emission).
Normal distribution of all data were first assessed with a Shapiro–Wilk test. Normally distributed data (cytotoxicity) are presented as column scatter plots with the mean of each group indicated by a horizontal line. These results were analyzed using three-way ANOVA with the local anesthetics, their concentration, and the presence or absence of TNF-α as factors to be tested. All other data (densitometry, migration), also presented as column scatter plots with a horizontal line indicating the mean, were analyzed using nonparametric testing methods (Kruskal-Wallis and Mann–Whitney U test). In order to maintain the family-wise error rate below 0.05, the result of multiple comparisons (Mann–Whitney U tests) following a statistically significant Kruskal–Wallis test were evaluated for significance by the Simes–Hochberg method. All tests were performed in a nonblinded and two-tailed manner with the SPSS Statistics Software Version 19 (IBM, Zurich, Switzerland). Graphs were generated using GraphPad Prism for Mac, Version 5 (GraphPad Software, La Jolla, CA). All experiments were performed at least three times. P < 0.05 was considered statistically significant.
Effect of Ropivacaine, Lidocaine, and Chloroprocaine on Cytotoxicity
First the cytotoxic effect of different local anesthetics was evaluated by measuring the activity of lactate dehydrogenase in cell culture supernatants after incubation of NCI-H838 lung cancer cells with different concentrations (1 nM, 1 μM, 10 μM, 100 μM) of ropivacaine, lidocaine, and chloroprocaine in the absence or presence of TNF-α at a concentration of 20 ng/ml for 4 h. Untreated cells served as control. The overall data analysis was conducted using three-way ANOVA. Cytotoxicity was the dependent factor and the type of local anesthetic, its concentration, and the presence or absence of TNF-α were the factors to be investigated. The analysis revealed that only the presence of TNF-α significantly increased cytotoxicity (P = <0.001). Neither the application of the different local anesthetics (P = 0.264) nor their different concentrations (P = 0.919) had any influence on cytotoxicity measures. An analysis of the interaction of the local anesthetics with their different concentrations (P = 0.908) or with TNF-α (P = 0.358) did not reach statistical significance. The same result could be observed for the combined analysis of TNF-α together with the different concentrations of the local anesthetics (P = 0.979) or a combination of all three factors (P = 0.992).
Effect of Ropivacaine on the Phosphorylation Status of Src and ICAM-1 in NCI-H838 Lung Cancer Cells
NCI-838 lung cancer cells were first incubated for 20 min with TNF-α at a concentration of 20 ng/ml in the presence or absence of different concentrations of ropivacaine (1 nM, 1 μM, 10 μM, 100 μM). Whole cell lysates were analyzed by Western blot analysis, probing for Src, phosphorylated at tyrosine 419 (pY419 Src) and total Src (fig. 1
Incubation of cells with ropivacaine alone for 20 min led to a significant decrease in phosphorylation of Src compared with untreated cells (= control) of 62% by 100 μM (P
= 0.003; fig. 1
B). Ten μM ropivacaine led to a 48% decrease, which was not considered statiscally significant (P
= 0.022, fig. 1
B). Coincubation of TNF-α with different concentrations of ropivacaine showed that ropivacaine also decreased the phosphorylation of Src at tyrosine 419 in a significant manner compared with TNF-α, alone even at 1 μM, by 52% (P
= 0.022, fig. 1
C). Higher concentrations of ropivacaine led to an even greater attenuation of TNF-α-induced Src phosphorylation (58% by 10 μM, P
= 0.006, and 60% by 100 μM, P
= 0.017; fig. 1
The same whole cell lysates were also analyzed via
Western blot probing for ICAM-1, phosphorylated at tyrosine 512 (pY512 ICAM-1) and total ICAM-1 (fig. 2
A). Increasing concentrations of ropivacaine did not alter the phosphorylation status of ICAM-1 (Kruskal–Wallis test, P
= 0.99; fig. 2
B), but coincubation with ropivacaine resulted in a significant attenuation of TNF-α-induced phosphorylation of ICAM-1 at tyrosine 512 compared with treatment with TNF-α alone, with significant inhibition beginning at 10 μM (40% decrease, P
= 0.01; fig. 2
C). A higher dose of ropivacaine further decreased TNF-α-induced ICAM-1 phosphorylation (71% by 100 μM, P
< 0.001; fig. 2
C). A 32% decrease by 1 μM was also observed but not considered statistically significant (P
= 0.031, fig. 2
Effect of Lidocaine on the Phosphorylation Status of Src and ICAM-1 in NCI-H838 Lung Cancer Cells
To evaluate the effect of lidocaine on NCI-H838 lung cancer cell Src signaling, cells were treated with increasing concentrations of lidocaine (1 nM, 1 μM, 10 μM, 100 μM) for 20 min and again analyzed for Src phosphorylation via
Western blot (fig. 3
A). Although a dose-dependent decrease in Src phosphorylation at tyrosine 419 was observed after incubation of the cells with lidocaine for 20 min, this decrease did not reach statistical significance (Kruskal–Wallis test, P
= 0.146; fig. 3
B). However, a significant decrease in TNF-α-induced Src phosphorylation of 73% was observed after coincubation of cells with TNF-α and 10 μM (P
= 0.012) of lidocaine (fig. 3
C). ICAM-1 phosphorylation in the Western blot (fig. 4
A) was not affected by lidocaine alone (Kruskal–Wallis test, P
= 0.624; fig. 4
B), but when coincubated with TNF-α, lidocaine reduced ICAM-1 phosphorylation compared with TNF-α alone in a significant manner (73% decrease by 100 μM, P
= 0.002; fig. 4
C). An attenuation of 50% was observed after coincubation of 1 μM lidocaine with TNF-α, but did not reach statistical significance (P
= 0.022; fig. 4
Effect of Chloroprocaine on the Phosphorylation Status of Src and ICAM-1 in NCI-H838 Lung Cancer Cells
To compare the results observed with the amide-linked local anesthetics (ropivacaine, lidocaine) with an ester-linked local anesthetic, NCI-H838 lung cancer cells were treated as above with increasing concentrations of the ester-linked chloroprocaine (1 nM, 1 μM, 10 μM, 100 μM). Analysis of Src phosphorylation (fig. 5
A) in H838 cell lysates showed that chloroprocaine had no effect on Src activation, either alone (Kruskal–Wallis test, P
= 0.305; fig. 5
B) or when coincubated with TNF-α compared with TNF-α alone (P
= 0.443; fig. 5
C). There was also no effect of chloroprocaine on ICAM-1 phosphorylation (fig. 6
A) after incubation with chloroprocaine alone compared with control (Kruskal–Wallis test, P
= 0.924; fig. 6
B), and after coincubation with TNF-α (P
= 0.217; fig. 6
Effect of Sodium Channel Activator Veratridine and Sodium-channel Blocker Tetrodotoxin on Phosphorylation Status of Src and ICAM-1 in NCI-H838 Lung Cancer Cells
To investigate whether the VGSC plays a role in activation of Src and subsequent phosphorylation of ICAM-1, NCI-H838 lung cancer cells were treated with the alkaloid and VGSC agonist veratridine at a concentration of 0.015 mM for 45 min before the cells were harvested, lysed, and prepared for Western blot analysis of pY419 Src and pY512 ICAM-1, as well as the total amounts of each protein (fig. 7
Ai and ii). This concentration was chosen because it was shown that 7.4 μM veratridine abolishes lidocaine-induced membrane depolarization of intestinal cells.22
For our experiments, we doubled this concentration. Densitometry analysis revealed that neither Src activation nor ICAM-1 phosphorylation was affected by treatment with veratridine compared with control (Kruskal–Wallis test, P
= 0.98; fig. 7
The effect of tetrodotoxin, a nonlocal anesthetic VGSC antagonist, was investigated. Tetrodotoxin at a concentration of 100 nM (10−7
M) was used, as this concentration is known to inhibit all VGSCs in excitable membranes.23
NCI-H838 lung cancer cells were pretreated with tetrodotoxin for 10 min before TNF-α (20 ng/ml) was added. Cells were lysed after 20 min. Representative Western blots of phosphorylated Src and ICAM-1 as well as the total amount of the proteins are shown in figure 7
Bi and ii. Densitometry analysis revealed no difference in Src and ICAM-1 phosphorylation after pretreatment with tetrodotoxin and subsequent addition of TNF-α compared with TNF-α alone (Mann–Whitney U-test, P
= 0.48 for Src and P
= 0.827 for ICAM-1; fig. 7
Biii and Biv).
Migratory Ability of NCI-H838 Lung Cancer Cells in the Presence of Ropivacaine, Lidocaine, and Chloroprocaine
NCI-H838 cells, stained with a fluorescent dye, were allowed to migrate through an 8-μM-pore polycarbonate membrane for 4 h in the presence or absence of different concentrations of ropivacaine, lidocaine, or chloroprocaine (1 pM, 1 nM, 1 μM, 10 μM, 100 μM). Migrated cells were detached from the bottom of the membrane and lysed. Fluorescence was measured at 485/535 nM (excitation/emission) (fig. 8
Compared with untreated cells (= control), ropivacaine induced a significant decrease in fluorescence – and therefore the number of cells migrated – by 26% (P
= 0.005) at 1 μM concentration. A higher concentration decreased fluorescence by 28% (10 μM, P
= 0.003; fig. 8
A). This effect was completely abolished by removal of ropivacaine after the initial 15 min of incubation (Kruskal–Wallis test, P
= 0.447; fig. 8
Treatment with lidocaine decreased fluorescence after 4 h of migration (Kruskal–Wallis test, P
= 0.004). 1 μM of lidocaine attenuated migration by 21% compared with control (P
= 0.004), whereas 10 μM and 100 μM led to a decrease of 23% (P
= 0.002) and 20% (P
= 0.009), respectively (fig. 8
B). In contrast, incubation with different concentrations of chloroprocaine had no effect on fluorescence measured after 4 h (Kruskal–Wallis test, P
= 0.718; fig. 8
The results of this study indicate that the amide-linked local anesthetics ropivacaine and lidocaine inhibit Src (auto)phosphorylation at tyrosine 419 induced by inflammatory stimuli such as TNF-α, and that ropivacaine inhibited Src phosphorylation (activity) even in the absence of inflammatory stimuli. In contrast, the ester-linked local anesthetic chloroprocaine had no such effect. In addition, we observed decreased Src-mediated phosphorylation of ICAM-1 at tyrosine 512 in presence of ropivacaine and lidocaine in NCI-H838 lung cancer cells treated with TNF-α (and lipopolysaccharide). Moreover, ropivacaine and lidocaine were shown to inhibit the migration of H838 cancer cells.
Interestingly, the inhibitory effect on either the phosphorylation of Src and ICAM-1 or migration of lung cancer cells was observed with amide local anesthetics (ropivacaine and lidocaine), but not with ester local anesthetics (chloroprocaine). Previous studies also demonstrated a selective protective effect of amide local anesthetics as compared with the ester-linked compounds. De Klaver et al.
demonstrated that lidocaine, ropivacaine, and bupivacaine protected endothelial cells against lipopolysaccharide-induced cellular injury, whereas procaine and tetracaine did not.24
Recently, Src tyrosine protein kinase has become a key research focus of cancer development, growth, and metastasis. Src is involved in signaling epithelial-to-mesenchymal transformation, e.g.
loss of E-cadherin and subsequently decreased cell-to-cell adhesion16
necessary for solid tumor metastasis.18
Src is activated either by (auto)phosphorylation at tyrosine 419 and/or by dephosphorylation at tyrosine 529.26
This study showed that ropivacaine dose-dependently decreased Src activation in NCI-H838 lung cancer cells, even in the absence of an inflammatory stimulus (TNF-α or lipopolysaccharide), although stimulation was necessary to observe an effect of ropivacaine on Src-dependent ICAM-1 phosphorylation at tyrosine 512. This indicates that Src might be the primary target of ropivacaine and that phosphorylation of ICAM-1 is attenuated secondary to the inhibition of Src activity, as ICAM-1 was previously shown to be a Src substrate.15
Local anesthetics are known to block the VGSC.27
The inhibitory effect of ropivacaine and lidocaine on Src activation and ICAM-1 phosphorylation, as observed in this study, is independent from the inhibition of the VGSC. No change in the phosphorylation status of the two proteins after incubation with the sodium channel agonist veratridine was observed. Neither Src nor ICAM-1 phosphorylation induced by TNF-α was altered by pretreatment with the sodium channel inhibitor tetrodotoxin. These results are in accordance with those of another study that demonstrated VGSC-independent inhibition of TNF-α-induced epithelial chemokine secretion.28
However, there is some evidence that VGSCs linked with Fyn, another member of the Src protein tyrosine kinase family, might play a role in the migration of neuronal cells and metastasis.29
Also, an inhibition of VGSCs in other human nonsmall-cell lung cancer cell lines led to a reduction of in vitro
invasion of these malignant cells.30
The identification of Src as a key enzyme in tumor growth and metastasis has led to the development of several “targeted therapies,” such as Src-inhibitors or combined Bcr/Abl and Src-inhibitors (e.g.
, Dasatinib®, Bristol-Myers Squibb, New York, NY).31
Most of these compounds act as adenosine triphosphate-competitive inhibitors at the adenosine triphosphate-binding pocket of Src.32
It would therefore be interesting to determine in future studies how ropivacaine inhibits Src activity, assessing for example whether it competes with adenosine triphosphate for binding within the Src kinase domain.33
ICAM-1, a member of the immunoglobulin superfamily of genes that play key roles in the binding of leukocytes to the vascular endothelium, is also involved in growth and metastasis of cancer. TNF-α stimulation of NCI-H838 cells (those used in the current study) for 16 h increased ICAM-1 expression.12
Increased expression of ICAM-1 could be linked to a more aggressive tumor phenotype34
and to enhanced leukocyte infiltration and binding to tumor cells.36
In addition, it was shown that A549 lung cancer cells overexpressing ICAM-1 exhibited enhanced in vitro
cell migration and in vivo
metastasis, an effect that could be inhibited by an anti-ICAM-1 antibody.35
This study focused on the phosphorylation of ICAM-1, which is necessary for rapid TNF-α-induced clustering of ICAM-1 resulting in enhanced neutrophil binding.15
The fact that ropivacaine and lidocaine inhibited this phosphorylation might be beneficial in the setting of metastasis. They might also attenuate the binding of circulating cancer cells to the vascular endothelium and therefore reduce transmigration and metastasis.
The well-established cytotoxic effect of local anesthetics, e.g.
, on neuronal cells,37
is not considered in the interpretation of our results. The concentrations of ropivacaine, lidocaine, and chloroprocaine used in this study showed that they did not induce cytotoxic effects after 4 h of treatment. In addition, an alteration in TNF-α-induced cytotoxicity in our lung cancer cell line was not observed.
Another finding was the inhibition of tumor cell migration by ropivacaine and lidocaine at 1 μM. Src is known to play a key role in cell migration, which is necessary for cancer cells to metastasize.18
It regulates cytoskeletal changes required for cell migration by phosphorylating proteins associated with focal adhesions and actin bundling, which control cell membrane protrusions.38
Src is also an upstream regulator of ρ family GTPases such as Rac and ρ, which together regulate dynamic changes in the cytoskeleton and control the disassembly of actin-based cytoskeletal structures and cell-matrix adhesions.17
We therefore hypothesize that the inhibition of tumor cell migration by amide local anesthetics is because of the inhibition of Src. The fact that the observed effect of inhibition of migration could be abolished by washout of the local anesthetic after 15 min (as shown for ropivacaine) also indicates, first, that the observed effect is not because of a cytotoxic effect of the local anesthetic, and second, that this effect is reversible.
It is well known that hematogenous dissemination of cancer cells occurs during the surgical resection of a tumor.40
Circulating tumor cells, detected in the blood 24 h postoperatively, are an independent prognostic marker for cancer recurrence because of the ability of these cells to extravasate and metastasize.41
In accordance with the results of our study, we suggest that the perioperative administration of local anesthetics may have the potential added benefit of attenuating extravasation and metastasis of circulating tumor cells before initiation of systemic treatment with cytotoxic agents.
Thus far, the potential beneficial effect of regional anesthesia to improve long-term outcome after cancer surgery has been attributed to inhibition of the surgical stress response and to the decrease in opioid requirements. It has been shown that opioids even at clinically useful concentrations might promote migration and proliferation of tumor cells, e.g.
, in breast cancer.42
This work reveals to the best of our knowledge a possible mechanism by which local anesthetics might be beneficial in patients with cancer and/or undergoing cancer surgery and that this mechanism may be because of, at least in part, inhibition of Src tyrosine kinase, a key enzyme in cancer growth and metastasis. Future studies will focus on establishing the molecular mechanism of Src inhibition and the influence of this inhibition on ICAM-1 phosphorylation and function with comparison with established Src inhibitors.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61:69–90
2. Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, Thetter O: Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: Results of a prospective randomized trial. Ann Surg 1998; 227:138–44
3. Chen ZL, Perez S, Holmes EC, Wang HJ, Coulson WF, Wen DR, Cochran AJ: Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85:493–8
4. Kim AW: Lymph node drainage patterns and micrometastasis in lung cancer. Semin Thorac Cardiovasc Surg 2009; 21:298–308
5. Sentürk M: New concepts of the management of one-lung ventilation. Curr Opin Anaesthesiol 2006; 19:1–4
6. Hollmann MW, Gross A, Jelacin N, Durieux ME: Local anesthetic effects on priming and activation of human neutrophils. ANESTHESIOLOGY 2001; 95:113–22
7. Blumenthal S, Borgeat A, Pasch T, Reyes L, Booy C, Lambert M, Schimmer RC, Beck-Schimmer B: Ropivacaine decreases inflammation in experimental endotoxin-induced lung injury. ANESTHESIOLOGY 2006; 104:961–9
8. Herroeder S, Pecher S, Schönherr ME, Kaulitz G, Hahnenkamp K, Friess H, Böttiger BW, Bauer H, Dijkgraaf OG, Durieux ME, Hollmann MW: Systemic lidocaine shortens length of hospital stay after colorectal surgery: A double-blinded, randomized, placebo-controlled trial. Ann Surg 2007; 246:192–200
9. Staudt LM: Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol 2010; 2:a000109
10. Hu G, Vogel SM, Schwartz DE, Malik AB, Minshall RD: Intercellular adhesion molecule-1-dependent neutrophil adhesion to endothelial cells induces caveolae-mediated pulmonary vascular hyperpermeability. Circ Res 2008; 102:e120–31
11. Roland CL, Harken AH, Sarr MG, Barnett CC Jr: ICAM-1 expression determines malignant potential of cancer. Surgery 2007; 141:705–7
12. Melis M, Spatafora M, Melodia A, Pace E, Gjomarkaj M, Merendino AM, Bonsignore G: ICAM-1 expression by lung cancer cell lines: Effects of upregulation by cytokines on the interaction with LAK cells. Eur Respir J 1996; 9:1831–8
13. Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP: Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 2001; 280:C814–22
14. Hu G, Minshall RD: Regulation of transendothelial permeability by Src kinase. Microvasc Res 2009; 77:21–5
15. Liu G, Vogel SM, Gao X, Javaid K, Hu G, Danilov SM, Malik AB, Minshall RD: Src phosphorylation of endothelial cell surface intercellular adhesion molecule-1 mediates neutrophil adhesion and contributes to the mechanism of lung inflammation. Arterioscler Thromb Vasc Biol 2011; 31:1342–50
16. Kim MP, Park SI, Kopetz S, Gallick GE: Src family kinases as mediators of endothelial permeability: Effects on inflammation and metastasis. Cell Tissue Res 2009; 335:249–59
17. Guarino M: Src signaling in cancer invasion. J Cell Physiol 2010; 223:14–26
18. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442–54
19. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE: Long-term survival after colon cancer surgery: A variation associated with choice of anesthesia. Anesth Analg 2008; 107:325–32
20. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. ANESTHESIOLOGY 2008; 109:180–7
21. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? ANESTHESIOLOGY 2006; 105:660–4
22. Barshack I, Levite M, Lang A, Fudim E, Picard O, Ben Horin S, Chowers Y: Functional voltage-gated sodium channels are expressed in human intestinal epithelial cells. Digestion 2008; 77:108–17
23. Catterall WA: Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol 1980; 20:15–43
24. de Klaver MJ, Weingart GS, Obrig TG, Rich GF: Local anesthetic-induced protection against lipopolysaccharide-induced injury in endothelial cells: The role of mitochondrial adenosine triphosphate-sensitive potassium channels. Anesth Analg 2006; 102:1108–13
25. Aleshin A, Finn RS: SRC: A century of science brought to the clinic. Neoplasia 2010; 12:599–607
26. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513–609
27. Owen MD, Dean LS: Ropivacaine. Expert Opin Pharmacother 2000; 1:325–36
28. Lang A, Ben Horin S, Picard O, Fudim E, Amariglio N, Chowers Y: Lidocaine inhibits epithelial chemokine secretion via
inhibition of nuclear factor kappa B activation. Immunobiology 2010; 215:304–13
29. Brackenbury WJ, Djamgoz MB, Isom LL: An emerging role for voltage-gated Na+ channels in cellular migration: Regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 2008; 14:571–83
30. Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S, Lei M, Bougnoux P, Gruel Y, Le Guennec JY: Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. Int J Biochem Cell Biol 2007; 39:774–86
31. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006; 49:6819–32
32. Schenone S, Bruno O, Radi M, Botta M: New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 2011; 31:1–41
33. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, Koch S, Schäfer W, Huber R, Engh RA: Crystal structures of active SRC kinase domain complexes. J Mol Biol 2005; 353:222–31
34. Schröder C, Witzel I, Möller V, Krenkel S, Wirtz RM, Jönicke F, Schumacher U, Milde-Langosch K: Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 2011; 137:1193–201
35. Lin YC, Shun CT, Wu MS, Chen CC: A novel anticancer effect of thalidomide: Inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006; 12:7165–73
36. Roland CL, Dineen SP, Toombs JE, Carbon JG, Smith CW, Brekken RA, Barnett CC Jr: Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Ex Biol Med (Maywood) 2010; 235:263–70
37. Perez-Castro R, Patel S, Garavito-Aguilar ZV, Rosenberg A, Recio-Pinto E, Zhang J, Blanck TJ, Xu F: Cytotoxicity of local anesthetics in human neuronal cells. Anesth Analg 2009; 108:997–1007
38. Horwitz AR, Parsons JT: Cell migration–movin' on. Science 1999; 286:1102–3
39. Yeatman TJ: A renaissance for SRC. Nature Rev Cancer 2004; 4:470–80
40. Ge MJ, Shi D, Wu QC, Wang M, Li LB: Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol 2006; 132:248–56
41. Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P: Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: A systematic review. Br J Cancer 2010; 102:1327–34
42. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491–8
43. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J: Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. Microvasc Res 2006; 72:3–11
© 2012 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.